Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study
- PMID: 24592492
- PMCID: PMC4381428
- DOI: 10.7326/M12-3046
Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study
Abstract
Background: Involvement of large arteries is well-documented in giant-cell arteritis (GCA), but the risk for cardiovascular events is not well-understood.
Objective: To evaluate the risks for incident myocardial infarction (MI), cerebrovascular accident (CVA), and peripheral vascular disease (PVD) in individuals with incident GCA in a general population context.
Design: Observational cohort study.
Setting: U.K. primary care database.
Patients: 3408 patients with incident GCA and 17 027 age- and sex-matched reference participants without baseline cardiovascular disease (MI, CVA, or PVD).
Measurements: Diagnoses of GCA, outcomes, and cardiovascular risk factors were identified from electronic medical records. One combined and 3 separate cohort analyses were conducted for the outcomes of MI, CVA, and PVD. The association of GCA with study outcomes is expressed with hazard ratios (HRs) with 95% CIs after adjustment for potential cardiovascular risk factors.
Results: Among 3408 patients with GCA (73% female; mean age, 73 years), the incidence rates of MI, CVA, and PVD were 10.0, 8.0, and 4.2 events per 1000 person-years, respectively, versus 4.9, 6.3, and 2.0 events per 1000 person-years, respectively, among reference participants. The HRs were 1.70 (95% CI, 1.51 to 1.91) for the combined outcome, 2.06 (CI, 1.72 to 2.46) for MI, 1.28 (CI, 1.06 to 1.54) for CVA, and 2.13 (CI, 1.61 to 2.81) for PVD. The HRs were more pronounced in the first month after GCA diagnosis (combined HR, 4.92 [CI, 2.59 to 9.34]; HR for MI, 11.89 [CI, 2.40 to 59.00]; HR for CVA, 3.93 [CI, 1.76 to 8.79]; HR for PVD, 3.86 [CI, 0.78 to 19.17]).
Limitation: Information on temporal arterial biopsies was not available, and there was a substantial amount of missing data on cardiovascular risk factors.
Conclusion: Giant-cell arteritis is associated with increased risks for MI, CVA, and PVD.
Primary funding source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Conflict of interest statement
Figures
Comment in
-
Summaries for patients. Heart attacks, strokes, and peripheral artery disease in patients with giant-cell arteritis.Ann Intern Med. 2014 Jan 21;160(2):1-22. doi: 10.7326/P14-9003. Ann Intern Med. 2014. PMID: 24592479 No abstract available.
-
Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis.Ann Intern Med. 2014 Aug 5;161(3):230. doi: 10.7326/L14-5015. Ann Intern Med. 2014. PMID: 25089867 No abstract available.
-
In response: risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis.Ann Intern Med. 2014 Aug 5;161(3):230. doi: 10.7326/L14-5015-2. Ann Intern Med. 2014. PMID: 25089868 No abstract available.
Summary for patients in
-
Summaries for patients. Heart attacks, strokes, and peripheral artery disease in patients with giant-cell arteritis.Ann Intern Med. 2014 Jan 21;160(2):1-22. doi: 10.7326/P14-9003. Ann Intern Med. 2014. PMID: 24592479 No abstract available.
Similar articles
-
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study.Arch Dermatol Res. 2023 Apr;315(3):429-435. doi: 10.1007/s00403-022-02369-5. Epub 2022 Jul 23. Arch Dermatol Res. 2023. PMID: 35871185
-
Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study.Rheumatology (Oxford). 2016 Jan;55(1):33-40. doi: 10.1093/rheumatology/kev262. Epub 2015 Aug 5. Rheumatology (Oxford). 2016. PMID: 26248811
-
The cardiovascular risk in bullous pemphigoid: Insights from a population-based study.Australas J Dermatol. 2024 Nov;65(7):e187-e193. doi: 10.1111/ajd.14355. Epub 2024 Aug 1. Australas J Dermatol. 2024. PMID: 39087452
-
Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies.Semin Arthritis Rheum. 2016 Dec;46(3):361-366. doi: 10.1016/j.semarthrit.2016.07.005. Epub 2016 Jul 21. Semin Arthritis Rheum. 2016. PMID: 27546492 Review.
-
Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study.Autoimmun Rev. 2023 Jun;22(6):103341. doi: 10.1016/j.autrev.2023.103341. Epub 2023 Apr 14. Autoimmun Rev. 2023. PMID: 37062441 Free PMC article. Review.
Cited by
-
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden.RMD Open. 2024 Apr 10;10(2):e003960. doi: 10.1136/rmdopen-2023-003960. RMD Open. 2024. PMID: 38599652 Free PMC article.
-
Chronic rheumatologic disorders and cardiovascular disease risk in women.Am Heart J Plus. 2023 Feb 9;27:100267. doi: 10.1016/j.ahjo.2023.100267. eCollection 2023 Mar. Am Heart J Plus. 2023. PMID: 38511090 Free PMC article. Review.
-
Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Front Neurol. 2023 Dec 7;14:1305093. doi: 10.3389/fneur.2023.1305093. eCollection 2023. Front Neurol. 2023. PMID: 38130834 Free PMC article. Review.
-
Exploring Cardiovascular Manifestations in Vasculitides: An In-Depth Review.Cureus. 2023 Aug 30;15(8):e44417. doi: 10.7759/cureus.44417. eCollection 2023 Aug. Cureus. 2023. PMID: 37791229 Free PMC article. Review.
-
Clinical Features and Outcomes of Japanese Patients with Giant Cell Arteritis: A Comparison with Takayasu Arteritis.J Pers Med. 2023 Feb 22;13(3):387. doi: 10.3390/jpm13030387. J Pers Med. 2023. PMID: 36983569 Free PMC article.
References
-
- Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8. - PubMed
-
- Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum. 1990;33:1074–87. - PubMed
-
- González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497–504. - PubMed
-
- Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211–7. - PubMed
-
- Agard C, Barrier JH, Dupas B, Ponge T, Mahr A, Fradet G, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59:670–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical